Logo image of CRDL

CARDIOL THERAPEUTICS INC-A (CRDL) Stock Fundamental Analysis

NASDAQ:CRDL - Nasdaq - CA14161Y2006 - Common Stock - Currency: USD

1.25  -0.03 (-2.34%)

After market: 1.25 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CRDL. CRDL was compared to 197 industry peers in the Pharmaceuticals industry. While CRDL seems to be doing ok healthwise, there are quite some concerns on its profitability. CRDL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CRDL had negative earnings in the past year.
In the past year CRDL has reported a negative cash flow from operations.
CRDL had negative earnings in each of the past 5 years.
In the past 5 years CRDL always reported negative operating cash flow.
CRDL Yearly Net Income VS EBIT VS OCF VS FCFCRDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -140.58%, CRDL is doing worse than 82.23% of the companies in the same industry.
With a Return On Equity value of -203.47%, CRDL is not doing good in the industry: 68.02% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -140.58%
ROE -203.47%
ROIC N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
CRDL Yearly ROA, ROE, ROICCRDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDL Yearly Profit, Operating, Gross MarginsCRDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

4

2. Health

2.1 Basic Checks

CRDL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CRDL has been increased compared to 5 years ago.
CRDL has a worse debt/assets ratio than last year.
CRDL Yearly Shares OutstandingCRDL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRDL Yearly Total Debt VS Total AssetsCRDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CRDL has an Altman-Z score of -3.83. This is a bad value and indicates that CRDL is not financially healthy and even has some risk of bankruptcy.
CRDL's Altman-Z score of -3.83 is in line compared to the rest of the industry. CRDL outperforms 41.62% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that CRDL is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.01, CRDL is doing good in the industry, outperforming 60.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -3.83
ROIC/WACCN/A
WACCN/A
CRDL Yearly LT Debt VS Equity VS FCFCRDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 3.26 indicates that CRDL has no problem at all paying its short term obligations.
With a Current ratio value of 3.26, CRDL perfoms like the industry average, outperforming 56.35% of the companies in the same industry.
A Quick Ratio of 3.26 indicates that CRDL has no problem at all paying its short term obligations.
CRDL has a better Quick ratio (3.26) than 61.42% of its industry peers.
Industry RankSector Rank
Current Ratio 3.26
Quick Ratio 3.26
CRDL Yearly Current Assets VS Current LiabilitesCRDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

CRDL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CRDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.86% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3%
EPS Next 2Y-22.47%
EPS Next 3Y17.78%
EPS Next 5Y37.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRDL Yearly Revenue VS EstimatesCRDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
CRDL Yearly EPS VS EstimatesCRDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRDL. In the last year negative earnings were reported.
Also next year CRDL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDL Price Earnings VS Forward Price EarningsCRDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDL Per share dataCRDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

CRDL's earnings are expected to grow with 17.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.47%
EPS Next 3Y17.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRDL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIOL THERAPEUTICS INC-A

NASDAQ:CRDL (5/29/2025, 8:00:00 PM)

After market: 1.25 0 (0%)

1.25

-0.03 (-2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners9.66%
Inst Owner Change2.46%
Ins Owners4.65%
Ins Owner ChangeN/A
Market Cap103.26M
Analysts82.86
Price Target7.19 (475.2%)
Short Float %2.56%
Short Ratio10.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.31%
Min EPS beat(2)29.97%
Max EPS beat(2)32.64%
EPS beat(4)3
Avg EPS beat(4)10.04%
Min EPS beat(4)-47.06%
Max EPS beat(4)32.64%
EPS beat(8)6
Avg EPS beat(8)8.61%
EPS beat(12)10
Avg EPS beat(12)13.6%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.17%
PT rev (3m)4.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.12
P/tB 8.12
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS0.15
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -140.58%
ROE -203.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.83%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.26
Quick Ratio 3.26
Altman-Z -3.83
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.14%
Cap/Depr(5y)17.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y-3%
EPS Next 2Y-22.47%
EPS Next 3Y17.78%
EPS Next 5Y37.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.92%
EBIT Next 3Y39.42%
EBIT Next 5Y46.2%
FCF growth 1Y10.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.12%
OCF growth 3YN/A
OCF growth 5YN/A